AZD4205
Dizal Pharmaceuticals
['t-cell lymphoma', 'ptcl', 'lymphoma', 'peripheral t-cell lymphoma', 'lymsm']
results from jackpot8 presented during the 2022 eha congress show that golidocitnib has encouraging anti-tumor efficacy and tolerable safety in patients with relapsed or refractory peripheral t-cell lymphoma. #ptcl #lymsm #eha 
Oncology news and insights from leading researchers and cancer centers.